Dalia Saleh | Cancer Cell Biology | Innovative Research Award

Posted on by sciencefather

Prof . Dalia Saleh | Cancer Cell Biology | Innovative Research Award

Prof . Dalia Saleh | National Research Centre | Egypt

Dr. Dalia Osama Abd El Fattah Saleh is a distinguished pharmacologist with over two decades of experience in experimental pharmacology and drug development. She holds a Ph.D. in Pharmacology from Cairo University and currently serves as a Professor at the National Research Centre in Cairo, Egypt. Dr. Saleh has contributed to numerous high-impact scientific journals and has led pioneering work in the areas of metabolic disorders, drug safety, and vascular pharmacology. Her multidisciplinary collaborations and continuous professional development from institutions like King’s College London demonstrate her dedication to excellence in research and education. She is also recognized for her commitment to academic instruction and quality assurance, having served as a Quality Assurance Director. Her work bridges scientific discovery and real-world therapeutic applications, making her a strong candidate for innovation-focused research awards.

publication profile:

scopus

Strengths for the Award:

  1. Robust Academic Background:
    Dr. Saleh holds a Ph.D. in Pharmacology from Cairo University and has a long-standing academic and research career in pharmacology and drug development. Her doctoral and master’s theses reflect a strong foundation in vascular pharmacology, metabolic disorders, and endocrine influence—fields of enduring relevance.

  2. Consistent Research Productivity:
    Her recent publication record (2022–2024) is prolific and impactful, with studies published in high-visibility journals such as Scientific Reports, Biochemistry and Cell Biology, Naunyn-Schmiedeberg’s Archives of Pharmacology, and Environmental Science and Pollution Research. Her work covers cutting-edge pharmacological topics, including:

    • AMPK/mTOR signaling pathways,

    • Neuroprotection and anti-inflammatory mechanisms,

    • Herbal and synthetic compounds in disease modulation,

    • Hepatic encephalopathy, diabetic nephropathy, and cystitis models.

  3. Interdisciplinary and Translational Approach:
    Dr. Saleh bridges basic pharmacological research with clinical relevance. Her investigations into molecular pathways (e.g., NF-κB, PI3K/Akt, SIRT-1) are grounded in disease models, thus demonstrating translational potential. Her inclusion of both natural and synthetic agents further adds diversity and innovation to her research.

  4. Capacity Building and International Exposure:
    She has participated in Continuing Professional Development modules at King’s College London, emphasizing drug safety, statistics, and ethics—key areas in modern drug development. This international engagement underscores her commitment to staying updated and aligned with global standards.

  5. Institutional Contribution and Leadership:
    As a Professor and former Quality Assurance Director at the National Research Centre (NRC), she has contributed to institutional excellence, including achieving ISO 9001/2008 certification. These roles reflect her leadership, organizational, and strategic planning skills.

Areas for Improvement:

  1. Principal Investigator Leadership:
    While her name appears consistently in multi-author studies, further highlighting her role as the principal investigator (PI) or corresponding author could strengthen her case for innovation leadership.

  2. Patents or Product Development:
    There is no mention of patents or direct product development based on her findings. Translating research into tangible therapeutics or clinical trials would significantly elevate her eligibility for innovation-specific awards.

  3. Global Collaborations and Grants:
    Although she has participated in international seminars, active global collaborations or leading major international grants/projects would further establish her as a global innovator.

  4. Public/Industry Impact:
    While the academic impact is strong, showcasing industry partnerships or policy-level influence (e.g., contributions to clinical guidelines or regulatory science) would align more directly with innovation awards that emphasize practical application.

🎓 Education Summary :

Dr. Dalia Saleh completed her higher education at Cairo University’s Faculty of Pharmacy, where she earned her Master of Science in Pharmacology in 2009 and Doctor of Philosophy in Pharmacology in 2012. Her M.Sc. thesis focused on the vascular and biochemical effects of rosiglitazone in diabetic rats, reflecting early interests in metabolic pharmacology. Her Ph.D. expanded on this foundation by exploring estrogen’s potential role in managing vascular changes related to insulin resistance. Both theses demonstrated robust experimental designs and contributed new insights into the interplay between hormonal and metabolic pathways in disease models. Dr. Saleh has since built on this academic background with advanced training in clinical drug development, safety, and biostatistics at King’s College London in 2023, indicating a continued commitment to integrating modern pharmaceutical science and translational research into her academic portfolio. This rich educational foundation underpins her success as a researcher and educator.

🔬 Research Focus :

Dr. Saleh’s research focuses on experimental pharmacology, with a special interest in metabolic diseases, drug-induced toxicities, inflammation, and vascular pharmacology. Her studies frequently involve animal models to investigate the mechanisms of drug action and to evaluate the protective or therapeutic roles of natural products and synthetic compounds. A recurring theme in her work is exploring the modulation of signaling pathways like AMPK, NF-κB, PI3K/mTOR, and Nrf2 in the context of oxidative stress, inflammation, and cellular apoptosis. She has also studied the role of hormonal influences in disease models, such as estrogen’s effect on insulin resistance. Her research employs modern analytical techniques and integrates molecular biology with pharmacodynamics to derive mechanistic insights. This strong focus on mechanistic pharmacology enhances her work’s relevance in drug development, particularly for conditions such as diabetic complications, hepatic encephalopathy, nephropathy, and chemotherapy-induced toxicities.

📚 Publications Top Note:

  1. 🧪 Eugenol alleviates acrylamide-induced testicular toxicity via AMPK/pAKT/mTOR modulation – Scientific Reports, 2024

  2. 🧠 Trimetazidine prevents cisplatin neuropathy through AMPK, Nrf2, and NF-κB pathways – Biochemistry and Cell Biology, 2023

  3. 🔬 Novel chromone-thiazolopyrimidines as TNF-α, IL-6, and PGE2 inhibitors – Polycyclic Aromatic Compounds, 2023

  4. 🚽 Chrysin protects against cyclophosphamide-induced hemorrhagic cystitis via anti-inflammatory signaling – Chemico-Biological Interactions, 2023

  5. 🧃 Linagliptin & L-arginine synergy in gastric hyperacidity via EP4 receptor upregulation – Naunyn-Schmiedeberg’s Archives of Pharmacology, 2023

  6. 🧠 L-arginine reduces thioacetamide-induced hepatic encephalopathy via NF-κB downregulation – Environmental Science and Pollution Research, 2023

  7. 🌿 Calotropis procera seed oil shows anti-inflammatory and antiparasitic activity – Arabian Journal of Chemistry, 2022

  8. 🛡️ Olmesartan mitigates diabetic nephropathy via AGE/PKC and TLR4/SIRT-1 pathways – European Journal of Pharmacology, 2022

  9. 🍃 Plumbago species show anti-fibrotic effects in liver fibrosis rat models – Scientific Reports, 2022

  10. 🫀 Omega-3 combats doxorubicin-induced liver toxicity via Nrf2/PI3K/Akt signaling – Pending Publication

Conclusion:

Dr. Dalia O. Saleh presents a strong candidacy for the Research for Innovative Research Award, particularly due to her sustained publication record, mechanistic depth in pharmacology, and commitment to professional development and institutional excellence. Her work spans innovative mechanistic explorations and novel therapeutic evaluations, showing real promise in addressing current pharmacological challenges.

Balbino Alarcón | Cancer Cell Biology | Best Researcher Award

Posted on by sciencefather

Prof. Dr. Balbino Alarcón | Cancer Cell Biology | Best Researcher Award

Prof. Dr. Balbino Alarcón , Consejo Superior de Investigaciones Científicas , Spain

Balbino Alarcón is a leading Spanish immunologist renowned for his contributions to T cell biology and immune signaling. Currently serving as Profesor de Investigación at the Consejo Superior de Investigaciones Científicas (CSIC), he has been affiliated with the Centro de Biología Molecular Severo Ochoa since 2002. His research has played a pivotal role in uncovering mechanisms of T cell receptor (TCR) signaling and immune system regulation. Dr. Alarcón holds a PhD in Biology from the Universidad Autónoma de Madrid, where he began shaping his scientific journey in the early 1980s. Over the decades, he has authored numerous impactful publications, many in top-tier journals, and holds several patents licensed to biotech companies. His work bridges fundamental immunology with translational applications in autoimmunity and cancer. With a keen focus on molecular signaling, his research continues to influence both basic science and therapeutic innovation in immunology.

Publication Profile:

Google Scholar

✅ Strengths for the Award:

  1. Outstanding Research Contributions:
    Dr. Alarcón has made seminal contributions to immunology, especially in T cell receptor (TCR) signaling, immune synapse formation, and immune cell communication. His work has appeared in top-tier journals like Cell, Immunity, Nature Communications, and Journal of Experimental Medicine.

  2. Impactful Publications & Citations:
    His research includes several highly cited papers (e.g., >500 citations), underlining the influence of his work on the broader scientific community.

  3. Translational Achievements:
    He holds multiple patents on immunomodulatory molecules (e.g., AX-024), which were licensed to biotech company Artax Biopharma, bridging basic science and clinical application.

  4. SARS-CoV-2 Research Leadership:
    He actively contributed to COVID-19 immunity research, developing flow cytometry-based antibody detection techniques and tracking longitudinal immune responses to infection and vaccination.

  5. Longevity and Commitment:
    Over 40 years of consistent research activity, with continuous affiliation to one of Spain’s most prestigious scientific institutions, CSIC.

  6. International Collaboration:
    He co-authored papers with leaders in immunology, showing global recognition and collaboration.

🛠️ Areas for Improvement:

  • Public Engagement & Visibility:
    Despite scientific acclaim, more visibility in public science communication, conference keynote roles, or leadership in global immunology consortia would further support his candidacy.

  • Mentorship Highlighting:
    While his academic stature suggests mentorship, documentation or awards for training young scientists could enhance his profile for broader awards recognizing holistic impact.

  • Innovation Metrics:
    Increased emphasis on clinical translation or successful product development from his patents could strengthen claims to innovation-driven recognitions.

🎓 Education:

Dr. Balbino Alarcón completed his undergraduate degree (Licenciado en Biología) in 1982 and his PhD in Biology with a specialization in Biochemistry in 1985, both from the Universidad Autónoma de Madrid, Spain. During his academic formation, he developed a deep interest in immunological signaling, particularly in how T cells communicate with their environment. His early education laid the foundation for a distinguished research career that has spanned more than three decades. His doctoral studies were focused on cellular and molecular immunology, equipping him with the tools to explore intricate signaling pathways. This robust educational background positioned him for leadership roles in immunological research, both nationally and internationally. Through rigorous academic training and continuous research contributions, Dr. Alarcón has become a key figure in advancing our understanding of T cell function and immune regulation.

👨‍🔬 Experience:

Dr. Balbino Alarcón has over 40 years of experience in immunological research, with a primary focus on T cell receptor (TCR) signaling and lymphocyte activation. Since July 27, 2002, he has held the position of Profesor de Investigación at the Consejo Superior de Investigaciones Científicas (CSIC), working at the Centro de Biología Molecular Severo Ochoa in Madrid, Spain. His academic and research career began with groundbreaking studies in T cell immunobiology, leading to discoveries such as the role of conformational changes in TCR activation. Dr. Alarcón has also been deeply involved in translational research, co-developing immunomodulatory drugs and securing patents that were licensed to Artax Biopharma. He regularly collaborates with leading immunologists and institutions worldwide, contributing to high-impact publications and international scientific reviews. His expertise and sustained contributions have made him a mentor and authority in molecular immunology and T cell biology.

🏅 Awards and Honors:

Dr. Balbino Alarcón’s distinguished career is highlighted by several prestigious awards and intellectual property recognitions. He co-developed two patented immunosuppressive strategies based on TCR signaling inhibition: one disrupting the TCR-Nck interaction and another involving chromene derivatives. Both patents were licensed to Artax Biopharma, showcasing the real-world therapeutic relevance of his research. He has authored highly cited publications, including foundational work published in Cell, Immunity, and Annual Review of Immunology, with citations in the hundreds. These contributions have not only advanced the field of immunology but also positioned Dr. Alarcón as a thought leader in immune signal transduction. He has been recognized nationally and internationally for his scientific achievements, serving as an editorial contributor and co-author of influential immunological reviews. His work continues to shape both academic and pharmaceutical research, making him a strong candidate for Best Researcher Awards.

🔬 Research Focus:

Dr. Alarcón’s research centers on the molecular mechanisms governing T cell receptor (TCR) activation and signal transduction. His work dissects how T cells recognize antigens and how intracellular signaling cascades translate these interactions into immune responses. A significant aspect of his research has involved understanding the conformational dynamics of the TCR/CD3 complex and how this affects T cell sensitivity and activation thresholds. He also explores the role of RRas2 in T and B cell function, including its relevance in lymphomagenesis and autoimmunity. Recently, he has contributed to understanding immune responses to SARS-CoV-2 and methods to detect neutralizing antibodies. His interdisciplinary approach integrates cell biology, molecular immunology, and translational research, linking fundamental science to clinical applications such as vaccine development and immunotherapy. By targeting TCR-associated pathways, Dr. Alarcón’s research opens new avenues in the treatment of immune-related diseases and cancer.

📚 Publications Top Notes:

  1. 🧫 RRas2 is required for germinal center formation to aid B cells during energetically demanding processes (Sci Signal, 2018)

  2. 🧪 A window of opportunity for cooperativity in the T Cell Receptor (Nat Commun, 2018)

  3. 🧬 Antigen phagocytosis by B cells is required for a potent humoral response (EMBO Rep, 2018)

  4. ⚙️ RRAS2 shapes the TCR repertoire by setting the threshold for negative selection (J Exp Med, 2019)

  5. 💊 Small molecule AX-024 targets T cell receptor signaling by disrupting CD3ε-Nck interaction (J Biol Chem, 2020)

  6. 🧪 Flow cytometry multiplexed method for the detection of Neutralizing human antibodies to SARS-CoV-2 (EMBO Mol Med, 2021)

  7. 🧬 Antigen presentation between T-cells drives Th17 polarization under limiting antigen (Cell Rep, 2021)

  8. 🧫 Detection of sustained humoral immune response (IgG + IgA) in SARS-CoV-2 infection (Sci Rep, 2021)

  9. 🧠 SFRP1 modulates astrocyte-to-microglia crosstalk in neuroinflammation (EMBO Rep, 2021)

  10. 💉 Longitudinal dynamics of SARS-CoV-2-specific immunity after infection or vaccination (PLoS Pathog, 2021)

🧾 Conclusion:

Dr. Balbino Alarcón is a highly deserving candidate for the Best Researcher Award. His pioneering studies in T cell signaling, impactful biomedical patents, and active role in immune response to infectious diseases demonstrate excellence in both basic and translational immunology. With decades of productive research, interdisciplinary collaboration, and consistent scientific leadership, he embodies the qualities celebrated by such an award.

Allegra Wundersitz | Signal Transduction Mechanisms | Young Scientist Award

Posted on by sciencefather

Mrs. Allegra Wundersitz | Signal Transduction Mechanisms | Young Scientist Award

Mrs. Allegra Wundersitz , RWTH Aachen University, Molekulare Ökologie der Rhizosphäre , Germany

Allegra Wundersitz is a passionate molecular biologist currently pursuing her PhD at RWTH Aachen University, Germany, in the group of Molecular Ecology of the Rhizosphere. Her research delves into the molecular mechanisms of plant oxygen sensing and the regulatory role of acyl-CoA-binding proteins (ACBPs) in stress signaling. Allegra has been recognized for her academic excellence, receiving the ISPA Poster Award and the Best Botanic Master’s Thesis Award from the German Society for Plant Sciences (DBG). With expertise in cloning, yeast-two-hybrid, luciferase complementation, and computational modeling, she seamlessly integrates biochemical and molecular approaches. Allegra actively collaborates with interdisciplinary teams, bridging plant physiology, structural biology, and molecular dynamics. Her commitment to research and mentoring makes her a promising young scientist aiming to contribute not only to fundamental plant science but also to translational applications in health and agriculture.

Publication Profile:

Orcid

✅ Strengths for the Award:

  • Innovative Research Focus: Allegra’s work on acyl-CoA-binding proteins (ACBPs) in plant oxygen sensing and stress signaling demonstrates high originality. Her approach of integrating protein biochemistry, gene regulation, and computational modeling is both novel and impactful.

  • Early Recognition: Despite being in the early stages of her career, she has received notable honors, including the ISPA Poster Award and the Best Master’s Thesis Award (DBG)—highlighting the quality and relevance of her work.

  • Interdisciplinary Collaboration: She engages with experts in molecular dynamics and structural biology, enriching her research with advanced modeling of protein mutations—showing strong collaborative and technical competencies.

  • Mentorship & Leadership: Supervising undergraduate students showcases her commitment to academic development and science communication.

  • Publication Record: Her first peer-reviewed article in New Phytologist indicates strong potential for growing her scientific influence.

🧩 Areas for Improvement:

  • Professional Engagement: Joining relevant scientific societies or organizations could enhance her visibility, offer networking opportunities, and provide access to grants or awards.

  • Industry Exposure: While her current focus is on basic science, even limited engagement with applied research or biotechnology partnerships could broaden the translational scope of her work.

  • Publication Volume: As her research matures, expanding her publication record beyond reviews into primary experimental studies will strengthen her academic profile.

🎓 Education:

Allegra Wundersitz holds a Master’s degree in Plant Molecular Biology, where her thesis on acyl-CoA-binding proteins (ACBPs) earned national recognition by the German Society for Plant Sciences in 2024. She is currently a PhD student at RWTH Aachen University, Germany, specializing in the molecular ecology of the rhizosphere. Her academic training spans core fields such as structural biochemistry, plant physiology, and gene regulation. Through hands-on learning and international workshops, she has developed technical proficiency in protein interaction assays, biosensor design, and in silico modeling. Her education emphasizes a multidisciplinary approach, blending experimental and computational biology. She has also supervised undergraduate research projects, further strengthening her academic leadership. Allegra’s educational journey reflects her deep curiosity for understanding molecular mechanisms in plant biology and their broader implications.

🧪 Experience:

Allegra’s experience is rooted in academic molecular biology research. During her Master’s and now as a PhD candidate, she has completed two significant research projects: developing plant-based oxygen biosensors and exploring the role of ACBPs in gene regulation. Her current PhD project investigates how ACBPs act as acyl-CoA receptors, mediating responses to oxygen and stress in plants. She employs techniques such as yeast two-hybrid assays, luciferase complementation, cloning, and molecular modeling. Allegra has also collaborated with experts in molecular dynamics, including Prof. Maria Fyta and Dr. Chandan Das, to simulate structural effects of ACBP mutations. She has presented her work at international conferences and received a prestigious poster award at ISPA. Allegra is gaining valuable teaching experience through undergraduate supervision, making her a well-rounded early-career scientist. Though she has not yet worked in industry, her work holds potential translational value in agriculture and health.

🔍 Research Focus:

Allegra’s research centers on the role of acyl-CoA-binding proteins (ACBPs) as key molecular players in plant oxygen sensing and stress signaling. She investigates how ACBPs function as acyl-CoA receptors and modulate gene expression through dynamic protein-protein interactions. Her goal is to uncover how lipid signals like acyl-CoAs are translated into physiological responses under stress conditions. Using a combination of experimental techniques—such as cloning, luciferase complementation assays, yeast-two-hybrid screens—and computational molecular dynamics, she deciphers the structural and functional aspects of ACBP interactions. Her research not only expands fundamental plant molecular biology but also contributes insights with potential applications in crop resilience, metabolic regulation, and even human health, given ACBPs’ links to cancer and metabolic disorders. Through interdisciplinary collaboration, Allegra aims to bridge structural biochemistry and plant physiology to understand how cells adapt to fluctuating oxygen and energy levels.

📚 Publications Top Notes:

  • 🧬 Acyl-CoA-binding proteins: bridging long-chain acyl-CoA metabolism to gene regulation – Tansley Insight, New Phytologist (April 22, 2025)

🧾 Conclusion:

Allegra Wundersitz is a highly promising young researcher who combines technical excellence, creativity, and interdisciplinary integration in her approach to plant molecular biology. Her foundational work on ACBPs not only deepens our understanding of plant stress responses but also hints at broader implications in health and metabolic research. With her trajectory and dedication, she is an ideal candidate for the Young Scientist Award, and this recognition would further support her impactful scientific journey.

ASLI CEYLAN | Molecular Mechanisms Signaling | Signal Transduction Award

Posted on by sciencefather

Prof. Dr. ASLI CEYLAN | Molecular Mechanisms Signaling | Signal Transduction Award

Prof. Dr. ASLI CEYLAN , Ankara Yildirim Beyazit University , Turkey

Dr. Aslı F. Ceylan is an accomplished pharmacologist and academic with a strong foundation in medical pharmacology and translational research. Born in Ankara, Turkey, in 1977, she has dedicated over two decades to advancing our understanding of cellular signaling pathways in disease states. After earning her degrees from Ankara University, she completed a prestigious postdoctoral fellowship at the University of Wyoming, where she began her international research journey. Currently serving at Ankara Yıldırım Beyazıt University School of Medicine, she contributes to both research and education. Fluent in Turkish, English, and Spanish, Dr. Ceylan bridges global scientific collaborations. Her work spans oxidative stress, inflammation, and cellular mechanisms in cardiovascular, metabolic, and neurodegenerative diseases. She is a prolific author and recipient of several international fellowships and project grants. Dr. Ceylan stands out as a dedicated scientist whose work contributes meaningfully to the field of signal transduction and molecular pharmacology.

Publication profile:

Orcid

✅ Strengths for the Award:

  1. Extensive Research in Signal Transduction Pathways
    Dr. Ceylan’s body of work demonstrates a consistent and high-impact focus on key signal transduction pathways—including NLRP3 inflammasome activation, mitophagy, ferroptosis, oxidative stress, and autophagy—across cardiovascular, metabolic, and neurological disease models.

  2. International Research Recognition
    She has held prestigious fellowships from NIH, the American Heart Association, and INBRE, contributing to globally relevant research while collaborating with international teams, especially in the U.S. and Europe.

  3. Strong Translational Relevance
    Her research links molecular mechanisms to potential therapies, such as her exploration of aldose reductase inhibitors, natural antioxidants, and neuroprotective compounds (e.g., rosemary extracts), bridging the gap between basic science and clinical relevance.

  4. Consistent Publication Record
    Dr. Ceylan has co-authored over a dozen peer-reviewed publications in the past three years alone, with topics directly tied to signal transduction, and published in reputable journals (e.g., Biochimica et Biophysica Acta, JACC: Basic to Translational Science).

  5. Leadership and Mentorship
    As a Principal Investigator for NIH-funded thematic research projects and an academic at a medical university, she demonstrates strong leadership, mentoring capabilities, and a sustained contribution to the scientific community.

🛠️ Areas for Improvement:

  1. Greater Focus on Human Clinical Studies
    While her animal model work is comprehensive, integrating more human cell or clinical data would increase the translational applicability of her research.

  2. Expanded Thematic Clarity in Signal Transduction
    Some of her recent works, while impactful, focus broadly on pharmacological effects of natural compounds. More thematic emphasis on specific intracellular signaling cascades (e.g., MAPK, PI3K/Akt, or JAK/STAT) could strengthen her profile specifically for a signal transduction-focused award.

  3. Visibility in Global Scientific Forums
    Increased participation as a speaker, panelist, or chair in international conferences focused on signal transduction would enhance her global academic footprint.

📘 Education:

Dr. Aslı F. Ceylan completed her entire academic training in Pharmacology at the prestigious Ankara University Faculty of Pharmacy. She earned her Bachelor of Science (B.Sc.) in Pharmacy in 1998, followed by a Master of Science (M.Sc.) in Pharmacology in 2001. Her strong interest in cellular mechanisms and drug interactions led her to pursue a Ph.D. in Pharmacology, which she successfully completed in 2007. Her doctoral research was further enhanced by a research fellowship at the National Institutes of Health (NIH) during 2004-2005, providing her hands-on experience in internationally recognized labs. This rigorous academic journey solidified her expertise in pharmacological mechanisms and preclinical modeling. Her academic training was consistently supported by competitive scholarships from the Turkish Scientific and Research Council (TÜBİTAK). Dr. Ceylan’s academic path reflects a deep commitment to understanding complex cellular systems and contributes significantly to her current role as a leader in molecular pharmacology and signal transduction.

💼 Experience:

Dr. Aslı F. Ceylan is currently a faculty member at Ankara Yıldırım Beyazıt University School of Medicine, where she serves in the Department of Medical Pharmacology. She has extensive academic and research experience spanning over 20 years. Her postdoctoral research at the University of Wyoming School of Pharmacy (2008–2009) focused on cardiovascular research, where she worked on signal transduction pathways involved in heart failure and metabolic disease. She also held a Principal Investigator (PI) role in NIH-funded INBRE research projects in the U.S. from 2011 to 2020. Dr. Ceylan has consistently contributed to multi-disciplinary research projects and collaborative studies, mentoring young researchers and postgraduate students. She has a solid background in oxidative stress, inflammation, and cellular apoptosis. Her translational approach, blending basic science with therapeutic innovation, aligns perfectly with the goals of signal transduction research. Her international exposure and consistent academic productivity make her a valuable asset to any scientific initiative.

🏆 Awards and Honors:

Dr. Aslı F. Ceylan has earned numerous national and international fellowships and honors throughout her career. She was awarded the Postdoctoral Fellowship by the American Heart Association and the University of Wyoming in 2008, which significantly propelled her research on cardiovascular signaling. She also received a Ph.D. research fellowship from the NIH (2004–2005), supporting her studies in cell signaling and oxidative stress. Domestically, she was funded by TÜBİTAK (Turkish Scientific and Research Council) for both her master’s and Ph.D. degrees. Most notably, she served as Principal Investigator for NIH INBRE Thematic Research Projects from 2011 to 2020, underlining her leadership and innovation in biomedical research. These accolades reflect her ongoing commitment to excellence in pharmacological science and her impact on the field of signal transduction, particularly in cardiovascular and neurodegenerative diseases. Her strong track record of competitive funding and recognition underscores her eligibility for the Signal Transduction Award.

🔬 Research Focus:

Dr. Ceylan’s research is centered on signal transduction pathways involved in oxidative stress, inflammation, mitophagy, and ferroptosis. Her work delves into the molecular mechanisms underlying cardiovascular diseases, diabetic complications, neurodegenerative disorders, and cancer, with a particular focus on mitochondrial function and cellular defense systems. She employs both in vivo and in vitro models to study how specific pharmacological agents modulate pathways like NLRP3 inflammasome activation, aldose reductase inhibition, and autophagy. Additionally, her recent research explores the therapeutic potential of natural compounds such as carnosol, carnosic acid, and rosemary extract in modulating redox balance and apoptotic pathways. Her interdisciplinary approach links natural product pharmacology with molecular signaling, making her contributions relevant across multiple domains. The translational value of her research, aiming to bridge the gap between bench and bedside, aligns directly with the core objectives of signal transduction studies and reinforces her eligibility for this distinguished award.

📚 Publications Top Notes:

  1. 🧬 Cardiomyocyte-specific deletion of endothelin receptor A obliterates cardiac aging via mitophagy and ferroptosis (2024)

  2. 🧫 Tackling chronic wound healing using nanomaterials: Advancements and future perspectives (2023)

  3. 🧪 Dual-acting aldose reductase inhibitor impedes oxidative stress in diabetic rat tissues (2023)

  4. 👁️ Cemtirestat induces ocular defense against glycotoxic stress in diabetic rats (2023)

  5. 🍷 NLRP3 inhibition protects against ethanol-induced cardiotoxicity in FBXL2-dependent manner (2023)

  6. 💉 Oxytocin and enalapril reduce epidural fibrosis post-laminectomy in rats (2023)

  7. 🧠 Calcium dobesilate therapy in cerebral hypoxia/reperfusion injury in rats (2023)

  8. 🧬 Beclin1 deficiency attenuates alcohol-induced cardiac dysfunction via ferroptosis inhibition (2022)

  9. 💓 Parkin insufficiency exacerbates cardiac remodeling through mitochondrial Ca2+ overload (2022)

  10. ❤️‍🩹 Beclin 1 haplosufficiency compromises stem-cell cardioprotection post-MI (2022)

🧾 Conclusion:

Dr. Aslı F. Ceylan is a highly qualified, internationally active, and academically productive researcher whose expertise lies in elucidating molecular mechanisms of disease through signal transduction pathways. Her deep involvement in studies on oxidative stress, mitochondrial dynamics, inflammation, and natural product pharmacology positions her as a valuable contributor to the advancement of molecular medicine.

Given her research output, grant leadership, and commitment to translational science, she is highly suitable for the Signal Transduction Award. Her work not only contributes to the understanding of intracellular signaling but also bridges basic research with therapeutic potential, making her a standout candidate for this recognition.

Jin-Feng Hu | Molecular Mechanisms Signaling | Distinguished Scientist Award

Posted on by sciencefather

Prof. Jin-Feng Hu | Molecular Mechanisms Signaling | Distinguished Scientist Award

Prof. Jin-Feng Hu , School of Pharmaceutical Sciences, Taizhou University, Zhejiang 318000, PR China ,China

Dr. Jin-Feng Hu is a globally recognized natural products chemist and currently serves as the Dean and Principal Investigator at the School of Pharmaceutical Sciences, Taizhou University, Zhejiang, China. With over three decades of academic and research experience, Dr. Hu has dedicated his career to discovering and developing bioactive natural products, particularly from rare and endangered plant species endemic to China. His contributions span innovative phytochemistry, drug discovery, and chemical biology. He has previously held prestigious academic positions at Fudan University and East China Normal University. Dr. Hu’s collaborations span continents, including Germany and the USA, contributing to an impressive international research profile. His work is widely published in high-impact journals and highly cited, underscoring the scientific relevance and translational potential of his discoveries.

Publication Profile:

Scopus

✅ Strengths for the Award:

  1. Prolific Contributions to Natural Products Chemistry
    Dr. Hu has made significant breakthroughs in phytochemical research, particularly focusing on rare and endangered Chinese plants, contributing both to drug discovery and biodiversity conservation.

  2. Global Research Experience
    His training and postdoctoral fellowships in leading institutions across China, Germany, and the USA (including the Hans-Knoell-Institute and the Scripps Research Institute) add to his international reputation and collaborative strength.

  3. Academic Leadership & Institutional Impact
    As a former department chair at Fudan University and current Dean at Taizhou University, Dr. Hu has not only led cutting-edge research but also shaped the academic direction of major pharmaceutical programs.

  4. High-Impact Publications
    Multiple first or last-author papers published in leading journals such as Phytochemistry, Organic Chemistry Frontiers, Bioorganic Chemistry, and Molecules—with a focus on pharmacologically relevant compounds.

  5. Innovative Research Themes
    Focused on drug resistance, inflammation, and metabolic diseases, using unique molecules like bis-diterpene heterodimers and sesquiterpenes, often with novel skeletons—this shows originality and translational potential.

⚙️ Areas for Improvement:

  1. Wider Public Recognition
    While he is highly respected in academic and pharmaceutical chemistry circles, broader science communication or participation in international awards/societies could boost global visibility.

  2. Commercialization & Patents
    Encouraging the translation of discoveries into patents or clinical trials would further highlight the real-world impact of his research.

  3. International Grant Funding
    Expansion into multinational funding sources (e.g., NIH, EU Horizon) would solidify global research integration and amplify the scale of his discoveries.

🎓 Education:

Dr. Hu earned his B.S., M.S., and Ph.D. degrees in Organic Chemistry from Lanzhou University (1986–1996). He pursued advanced training and postdoctoral research in Natural Products Chemistry at the Institute of Materia Medica, Chinese Academy of Medical Sciences, followed by a prestigious BMBF Fellowship at the Hans-Knoell-Institute (HKI) in Germany. Dr. Hu then continued his postdoctoral work in the United States—first at the University of Mississippi focusing on natural products chemistry and later at the Genomics Institute of the Novartis Research Foundation/The Scripps Research Institute, in the laboratory of renowned chemist Prof. Peter G. Schultz. His academic journey across leading institutions in China, Germany, and the US provided a robust foundation in interdisciplinary sciences and global perspectives in medicinal chemistry.

🧪 Experience:

Dr. Hu currently serves as Full Professor, Principal Investigator, and Dean of the School of Pharmaceutical Sciences at Taizhou University (2021–present). Before this, he was Chair of the Department of Natural Products Chemistry at Fudan University (2011–2021), and prior to that, Deputy Director of the MOE Key Laboratory of Brain Functional Genomics at East China Normal University (2006–2011). In each position, he has led cutting-edge research in natural products, coordinated multi-institutional collaborations, mentored numerous young scientists, and managed institutional development. His lab integrates phytochemistry, structural biology, and drug discovery platforms, focusing particularly on therapeutic leads for antimicrobial resistance, cancer, and metabolic diseases. With a career that reflects both academic excellence and applied innovation, Dr. Hu has significantly contributed to China’s leadership in pharmaceutical science.

🏆 Awards and Honors:

Dr. Hu has received multiple national and international honors, including fellowships, research grants, and awards recognizing his excellence in natural products chemistry. He was a BMBF Research Fellow in Germany, a Postdoctoral Fellow at the Novartis Genomics Institute and The Scripps Research Institute in the US, and has been a recipient of several Chinese National Natural Science Foundation awards. His leadership roles at prestigious institutions like Fudan University and East China Normal University reflect the esteem he holds within the academic community. Moreover, his publications are widely cited, and his research frequently garners attention for its innovation and societal relevance, especially in the context of preserving biodiversity and discovering drugs from endangered species. These achievements make him an outstanding candidate for a Distinguished Scientist Award.

🔬 Research Focus:

Dr. Hu’s research is centered on the discovery and development of novel bioactive compounds from rare and endangered plants endemic to China. His work emphasizes the interface of phytochemistry, chemical biology, and drug discovery, employing integrative analytical techniques like NMR, LC-MS, and bioassays. A major focus is the identification of natural inhibitors of key metabolic enzymes such as ATP-citrate lyase and ACC1, with applications in metabolic disorders and cancer. His studies also target drug-resistant bacterial infections, inflammation, and neurodegenerative diseases. By studying plants that are ecologically valuable yet scientifically underexplored, Dr. Hu not only contributes to new therapeutic leads but also aids in conservation biology and chemotaxonomy. His approach of combining traditional Chinese medicinal knowledge with modern molecular science marks him as a trailblazer in natural products-based drug discovery.

📚 Publication Top Notes:

  1. 🌲 Spiroamentotaxols A−D from Amentotaxus yunnanensis and their bioactivities – Organic Chemistry Frontiers (2025)

  2. 🍃 Fortunefuroic acids from Keteleeria fortunei via integrated dereplication approach – Phytochemistry (2025)

  3. 🌿 Benzofurans from Parrotia subaequalis with antimicrobial activity – Phytochemistry (2025)

  4. 🌸 Bis-iridoid glycosides and triterpenoids from Kolkwitzia amabilis targeting ACC1 and ACL – Molecules (2024)

  5. 🍂 Platanosides from Platanus acerifolia against drug-resistant infections – Bioorganic Chemistry (2024)

  6. 🌼 Natural products from Heptacodium miconioides and their classification significance – Phytochemistry (2024)

  7. 🌲 Tsugaforrestiacids A–O from Tsuga forrestii with ATP-citrate lyase inhibition – Phytochemistry (2024)

  8. 🌲 Terpenoids from Pseudotsuga forrestii as DRAK2 inhibitors – Journal of Molecular Structure (2024)

  9. 🍁 Anti-inflammatory flavonoids from Platanus acerifolia leaves – Phytochemistry Letters (2024)

  10. 🌴 Fortunefuroic acid J from Keteleeria hainanensis with dual inhibitory effects – Chemistry & Biodiversity (2024)

🔚 Conclusion:

Dr. Jin-Feng Hu is an exceptionally qualified candidate for the Distinguished Scientist Award. His trailblazing research in natural products chemistry, strategic leadership in academic institutions, and commitment to preserving biodiversity through medicinal innovation position him as a thought leader in his field. His work not only expands the scientific frontier of phytochemical drug discovery but also addresses urgent global health concerns such as antibiotic resistance and metabolic disease. Recognizing Dr. Hu with this award would honor a career devoted to science, mentorship, and societal benefit, while also empowering his continued excellence in the years to come.

Lijuan Deng | Molecular Mechanisms Signaling | Molecular Cell Biology Award

Posted on by sciencefather

Mrs. Lijuan Deng | Molecular Mechanisms Signaling | Molecular Cell Biology Award

Mrs. Lijuan Deng , Zhongshan Institute for Drug Discovery , China

Lijuan Deng is a passionate graduate student researcher at the Zhongshan Institute for Drug Discovery in China, specializing in the molecular mechanisms underlying metabolic diseases. Her scientific curiosity centers on gene regulation, signaling pathways, and metabolic dysregulation in disease progression, particularly metabolic-associated fatty liver disease (MASLD). Her translational approach blends experimental models and bioinformatics to bridge basic science and therapeutic innovation. Lijuan has already co-authored a publication in The FASEB Journal, identifying CDKN1A as a key regulator in MASLD. She is also the inventor of a patent-pending technique for nascent RNA labeling in extracellular vesicles. Through collaborations with clinical researchers and a solid foundation in molecular biology techniques, she is positioning herself as a rising talent in cell biology. Her work promises to advance understanding and treatment of metabolic diseases.

Publication Profile:

Orcid

✅ Strengths for the Award:

  1. Innovative Research: Lijuan Deng has significantly contributed to the understanding of MASLD (Metabolic-Associated Steatotic Liver Disease) by identifying CDKN1A as a key regulatory gene through integrated transcriptomic analysis and experimental validation.

  2. Translational Focus: Her research bridges molecular biology and clinical application, enhancing its impact in drug discovery and disease diagnostics.

  3. Publication Record: She is the first author of a peer-reviewed article published in The FASEB Journal (SCI-indexed), showcasing her ability to conduct and communicate high-quality research.

  4. Patent Innovation: She holds a pending patent for a novel method involving nascent RNA labeling in extracellular vesicles, showing her drive toward technological advancement and biomedical innovation.

  5. Collaborative Approach: Active collaboration with the Department of Endocrinology at Shenzhen Second People’s Hospital reflects strong interdisciplinary and clinical integration.

🧩 Areas for Improvement:

  1. Expanded Publication Portfolio: Increasing the number of peer-reviewed articles will strengthen her academic visibility and impact.

  2. Professional Networking: Engagement in international cell biology societies or conferences and obtaining professional memberships can support broader recognition and growth.

  3. Editorial/Leadership Roles: Participation in editorial boards, review panels, or student leadership roles can enrich her professional development profile.

🎓 Education:

Lijuan Deng is currently pursuing her graduate studies in molecular biology at the Zhongshan Institute for Drug Discovery, where she focuses on translational biomedical research. Her academic foundation includes advanced coursework in biochemistry, molecular genetics, and cellular signaling. Through structured academic training, she has acquired proficiency in modern laboratory methods, including RNA sequencing, qPCR, western blotting, and exosome analysis. Her education emphasizes critical thinking and scientific rigor, enabling her to design experiments, analyze data, and interpret biological outcomes. She regularly participates in academic seminars, journal clubs, and collaborative workshops to refine her scientific acumen. Her thesis research is centered around identifying novel molecular targets in MASLD, a field gaining global relevance. Lijuan’s education is not only shaping her technical capabilities but also nurturing her ambition to contribute to impactful, real-world medical solutions through cell biology research.

💼 Experience:

Lijuan Deng has gained extensive laboratory experience as a graduate student researcher at the Zhongshan Institute for Drug Discovery. Her hands-on work includes both cellular and animal models, with a strong focus on metabolic disease mechanisms. She played a key role in identifying CDKN1A as a potential MASLD progression factor, combining transcriptomic data analysis with molecular validation. Additionally, she has worked on exosome-based biomarker discovery and developed a patent-pending method for nascent RNA labeling. She collaborates with the Department of Endocrinology at Shenzhen Second People’s Hospital, providing a clinical dimension to her work. Though early in her career, her contributions to translational research are already making an impact. She is skilled in molecular biology, gene expression profiling, and therapeutic target screening. Her research experience has been shaped by interdisciplinary collaboration, scientific publications, and the ambition to innovate within the field of molecular cell biology.

🧬 Research Focus:

Lijuan Deng’s research is primarily focused on the molecular underpinnings of metabolic-associated fatty liver disease (MASLD), a key manifestation of metabolic syndrome. She investigates how dysregulated genes, signaling networks, and lipid metabolism contribute to disease initiation and progression. A major highlight of her work is identifying CDKN1A as a potential risk factor in MASLD using integrated bioinformatics and experimental techniques. Additionally, she explores the utility of extracellular vesicles as carriers of diagnostic biomarkers and therapeutic molecules. Her patent-pending work involves a novel method for labeling nascent RNA within exosomes, opening possibilities for tracking dynamic RNA communication in disease contexts. Her research strategy merges molecular biology with disease modeling, aiming to bridge laboratory discoveries with potential therapeutic strategies. Through strong collaborations and a translational research outlook, Lijuan is dedicated to uncovering actionable insights that can inform drug development for complex metabolic disorders.

📚 Publications Top Notes:

  • 🧾 “Identification of CDKN1A as a potential key risk factor in MASLD progression.” – The FASEB Journal, 2025. DOI: 10.1096/fj.202402942R

🧾 Conclusion:

Lijuan Deng stands out as an emerging researcher with strong foundations in molecular cell biology and a clear orientation toward translational science. Her innovative work in MASLD, combined with an SCI publication and a pending patent, make her a highly suitable and promising candidate for the Molecular Cell Biology Award. While she is in the early stages of her career, her achievements thus far indicate substantial potential for future contributions to the field.